The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Neznanov N.G.

V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology;
First Pavlov State Medical University

Tanashyan M.M.

Research Center of Neurology

Akarachkova E.S.

Almatek LLC — Rehabilitation Center «Rehaline»

Amelin A.V.

First Pavlov State Medical University

Bogolepova A.N.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center for Brain and Neurotechnology

Vasilieva A.V.

V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology;
Mechnikov Northwestern State Medical University

Ermolenko N.A.

Burdenko Voronezh State Medical University

Zakharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

Lebedeva A.V.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center for Brain and Neurotechnology

Maksimova M.Yu.

Research Center of Neurology

Medvedev V.E.

Peoples’ Friendship University of Russia named after Patrice Lumumba

Mendelevich V.D.

Kazan State Medical University

Solovieva E.Yu.

Pirogov Russian National Research Medical University (Pirogov University)

Tabeeva G.R.

Sechenov First Moscow State Medical University (Sechenov University)

Fedosenko S.V.

Siberian State Medical University

Comorbid anxiety disorders in patients with neurological pathology: current state of the problem and the role of etifoxine in treatment strategy

Authors:

Neznanov N.G., Tanashyan M.M., Akarachkova E.S., Amelin A.V., Bogolepova A.N., Vasilieva A.V., Ermolenko N.A., Zakharov V.V., Lebedeva A.V., Maksimova M.Yu., Medvedev V.E., Mendelevich V.D., Solovieva E.Yu., Tabeeva G.R., Fedosenko S.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(12): 126‑136

DOI: 10.17116/jnevro2024124121126

Views: 922

Downloaded: 4

Buy for 300₽
Contact the author
Table of contents

COMORBID ANXIETY DISORDERS IN PATIENTS WITH NEUROLOGICAL PATHOLOGY: CURRENT STATE OF THE PROBLEM AND THE ROLE OF ETIFOXINE IN TREATMENT STRATEGY
COMORBID ANXIETY DISORDERS IN PATIENTS WITH NEUROLOGICAL PATHOLOGY: CURRENT STATE OF THE PROBLEM AND THE ROLE OF ETIFOXINE IN TREATMENT STRATEGY

To cite this article:

Neznanov NG, Tanashyan MM, Akarachkova ES, et al. . Comorbid anxiety disorders in patients with neurological pathology: current state of the problem and the role of etifoxine in treatment strategy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(12):126‑136. (In Russ.)
https://doi.org/10.17116/jnevro2024124121126

 
 
Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Long-term follow-up of adult patients with serial and status course of epileptic seizures. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):63-68
Posttraumatic stress diso­rder clinical guidelines and treatment standards: focus on the symptoms of the psychophysiological arousal. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):58-68
Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137
Trait and state anxiety, symptoms of inso­mnia and their influence on daytime functioning in adolescent girls. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):66-71
Reco­gnan (citicoline) in the correction of asthenic and anxiety-depressive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):43-47
Epilepsy with PCDH19 muta­tion: poly­pharmacy as a consequence of the complexity and dive­rsity of pathogenesis mechanisms. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):51-55
The asso­ciation of single-nucleotide poly­morphism rs6265 of the brain-derived neurotrophic factor gene with clinical features in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):82-88
Study of the practice of prescribing phenosanic acid in epilepsy acco­mpanied by asthenic diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):89-97
Surgical treatment of congenital and acquired inte­rnal caro­tid artery tortuosity in patients with ocular ischemic syndrome. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(3):272-278
Oral seda­tion in pediatric outpatient dentistry. Stomatology. 2024;(3):42-49

The article presents theses of the resolution of the Interdisciplinary Council of Experts in Psychiatry and Neurology (Moscow, 2024) on the issue of comorbid anxiety disorders (AD) in patients with neurological pathologies. The authors highlight the high prevalence of comorbid ADs and their significant negative impact on the course of underlying diseases, such as epilepsy, pain syndromes and post-stroke conditions. Modern approaches to the diagnosis and treatment of ADs in this group of patients are discussed. Special attention is given to the role of etifoxine as an effective anxiolytic in the comprehensive therapy of ADs. Etifoxine, due to its dual mechanism of action on GABA receptors, demonstrates high efficacy in reducing anxiety and has neuroprotective, neurotrophic, neuroplastic, analgesic, and anti-inflammatory properties, making it an important tool in the treatment of comorbid ADs in patients with neurological pathologies. The article also reviews recently published data confirming its efficacy and favourable safety profile compared to traditional benzodiazepines and other anxiolytic drugs.

Keywords:

etifoxine
anxiety
anxiety disorder
comorbid anxiety
pain syndromes
epilepsy
neurodegenerative disease
post-stroke anxiety
transient ischemic attack
generalized anxiety disorder
adjustment disorder
phobias

Authors:

Neznanov N.G.

V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology;
First Pavlov State Medical University

Tanashyan M.M.

Research Center of Neurology

Akarachkova E.S.

Almatek LLC — Rehabilitation Center «Rehaline»

Amelin A.V.

First Pavlov State Medical University

Bogolepova A.N.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center for Brain and Neurotechnology

Vasilieva A.V.

V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology;
Mechnikov Northwestern State Medical University

Ermolenko N.A.

Burdenko Voronezh State Medical University

Zakharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

Lebedeva A.V.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center for Brain and Neurotechnology

Maksimova M.Yu.

Research Center of Neurology

Medvedev V.E.

Peoples’ Friendship University of Russia named after Patrice Lumumba

Mendelevich V.D.

Kazan State Medical University

Solovieva E.Yu.

Pirogov Russian National Research Medical University (Pirogov University)

Tabeeva G.R.

Sechenov First Moscow State Medical University (Sechenov University)

Fedosenko S.V.

Siberian State Medical University

Received:

06.11.2024

Accepted:

29.11.2024

List of references:

  1. Moser DK, Riegel B, McKinley S, et al. Impact of anxiety and perceived control on in-hospital complications after acute myocardial infarction. Psychosom Med. 2007;69(1):10-16.  https://doi.org/10.1097/01.psy.0000245868.43447.d8
  2. DeJean M, Giacomini M, Vanstone M, Brundisini F. Patient experiences of depression and anxiety with chronic disease: A systematic review and qualitative meta-synthesis. Ont Health Technol Assess Ser. 2013;13(16):1-33. 
  3. Mohammadi MR, Pourdehghan P, Mostafavi SA, et al. Generalized anxiety disorder: Prevalence, predictors, and comorbidity in children and adolescents. J Anxiety Disord. 2020;73:102234. https://doi.org/10.1016/j.janxdis.2020.102234
  4. Szuhany KL, Simon NM. Anxiety Disorders: A Review. JAMA. 2022;328(24):2431-2445. https://doi.org/10.1001/jama.2022.22744
  5. Noyes R Jr. Comorbidity in generalized anxiety disorder. Psychiatr Clin North Am. 2001;24(1):41-55.  https://doi.org/10.1016/s0193-953x(05)70205-7
  6. Sadock E, Auerbach SM, Rybarczyk B, et al. The relationship of life stressors, mood disorder, and health care utilization in primary care patients referred for integrated behavioral health services. J Nerv Ment Dis. 2014;202(10):763-766.  https://doi.org/10.1097/NMD.0000000000000195
  7. Willgoss T, Yohannes A, Goldbart J, Fatoye F. COPD and anxiety: its impact on patients’ lives. Nurs Times. 2011;107(15-16):16-19. 
  8. Bailey PH. The dyspnea-anxiety-dyspnea cycle-COPD patients’ stories of breathlessness: «It’s scary /when you can’t breathe». Qual Health Res. 2004;14(6):760-778.  https://doi.org/10.1177/1049732304265973
  9. Knapp P, Dunn-Roberts A, Sahib N, et al. Frequency of anxiety after stroke: An updated systematic review and meta-analysis of observational studies. Int J Stroke. 2020;15(3):244-255.  https://doi.org/10.1177/1747493019896958
  10. Ignacio KHD, Muir RT, Diestro JDB, et al. Prevalence of depression and anxiety symptoms after stroke in young adults: A systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2024;33(7):107732. https://doi.org/10.1016/j.jstrokecerebrovasdis.2024.107732
  11. Broomfield NM, Scoular A, Welsh P, et al. Poststroke anxiety is prevalent at the population level, especially among socially deprived and younger age community stroke survivors. Int J Stroke. 2015;10(6):897-902.  https://doi.org/10.1111/ijs.12109
  12. Menlove L, Crayton E, Kneebone I, et al. Predictors of anxiety after stroke: a systematic review of observational studies. J Stroke Cerebrovasc Dis. 2015;24(6):1107-1117. https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.12.036
  13. Wright F, Wu S, Chun HY, Mead G. Factors Associated with Poststroke Anxiety: A Systematic Review and Meta-Analysis. Stroke Res Treat. 2017;2017:2124743. https://doi.org/10.1155/2017/2124743
  14. Zhang S, Cheng S, Zhang Z, et al. Related risk factors associated with post-stroke fatigue: a systematic review and meta-analysis. Neurol Sci. 2021;42(4):1463-1471. https://doi.org/10.1007/s10072-020-04633-w
  15. Chun HY, Ford A, Kutlubaev MA, et al. Depression, Anxiety, and Suicide After Stroke: A Narrative Review of the Best Available Evidence. Stroke. 2022;53(4):1402-1410. https://doi.org/10.1161/STROKEAHA.121.035499
  16. Tang WK, Wang LF, Tsoi KK, et al. Post-Traumatic Stress Disorder after Stroke: A Systematic Review. Neurol India. 2022;70(5):1887-1895. https://doi.org/10.4103/0028-3886.359285
  17. Sadock BJ, Sadock VA, Ruiz P. Compendium of psychiatry: behavioral science and clinical psychiatry. 11th ed. Porto Alegre: Artmed. 2017;723-726. 
  18. Josephson CB, Jetté N. Psychiatric comorbidities in epilepsy. Int Rev Psychiatry. 2017;29(5):409-424.  https://doi.org/10.1080/09540261.2017.1302412
  19. Colmers PLW, Maguire J. Network Dysfunction in Comorbid Psychiatric Illnesses and Epilepsy. Epilepsy Curr. 2020;20(4):205-210.  https://doi.org/10.1177/1535759720934787
  20. Yogarajah M, Mula M. Social cognition, psychiatric comorbidities, and quality of life in adults with epilepsy. Epilepsy Behav. 2019;100(Pt B):106321. https://doi.org/10.1016/j.yebeh.2019.05.017
  21. Rodríguez CA, Kubis MM, Arteaga CBT, Fustes OJH. Psychiatric Comorbidities in Epilepsy. J Epilepsy Res. 2022;12(1):21-26.  https://doi.org/10.14581/jer.22004
  22. Scott AJ, Sharpe L, Loomes M, Gandy M. Systematic Review and Meta-Analysis of Anxiety and Depression in Youth With Epilepsy. J Pediatr Psychol. 2020;45(2):133-144.  https://doi.org/10.1093/jpepsy/jsz099
  23. Zhong R, Chen Q, Zhang X, et al. Depressive and Anxiety Symptoms Are Predictors of Seizure Recurrence in Adults With Newly Diagnosed Epilepsy. Front Psychiatry. 2021;12:784737. https://doi.org/10.3389/fpsyt.2021.784737
  24. Scott AJ, Sharpe L, Hunt C, Gandy M. Anxiety and depressive disorders in people with epilepsy: a meta-analysis. Epilepsia. 2017;58:973-982. 
  25. Nogueira MH, Yasuda CL, Coan AC, et al. Concurrent mood and anxiety disorders are associated with pharmacoresistant seizures in patients with MTLE. Epilepsia. 2017;58:1268-1276.
  26. Asmundson GJ, Katz J. Understanding the co-occurrence of anxiety disorders and chronic pain: state-of-the-art. Depress Anxiety. 2009;26(10):888-901.  https://doi.org/10.1002/da.20600
  27. Mullins PM, Yong RJ, Bhattacharyya N. Associations between chronic pain, anxiety, and depression among adults in the United States. Pain Pract. 2023;23(6):589-594.  https://doi.org/10.1111/papr.13220
  28. Aquin JP, El-Gabalawy R, Sala T, Sareen J. Anxiety Disorders and General Medical Conditions: Current Research and Future Directions. Focus (Am Psychiatr Publ). 2017;15(2):173-181.  https://doi.org/10.1176/appi.focus.20160044
  29. Naranjo C, Del Reguero L, Moratalla G, et al. Anxiety, depression and sleep disorders in patients with diabetic neuropathic pain: a systematic review. Expert Rev Neurother. 2019;19(12):1201-1209. https://doi.org/10.1080/14737175.2019.1653760
  30. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328.  https://doi.org/10.1136/annrheumdis-2016-209724
  31. Song TJ, Cho SJ, Kim WJ, et al. Anxiety and Depression in Tension-Type Headache: A Population-Based Study. PLoS One. 2016;11(10):e0165316. https://doi.org/10.1371/journal.pone.0165316
  32. Karimi L, Crewther SG, Wijeratne T, et al. The Prevalence of Migraine With Anxiety Among Genders. Front Neurol. 2020;11:569405. https://doi.org/10.3389/fneur.2020.569405
  33. McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain. 2004;111(1-2):77-83.  https://doi.org/10.1016/j.pain.2004.06.002
  34. Crombez G, Eccleston C, Van Damme S, et al. Fear-avoidance model of chronic pain: the next generation. Clin J Pain. 2012;28(6):475-483.  https://doi.org/10.1097/AJP.0b013e3182385392
  35. Zale EL, Lange KL, Fields SA, Ditre JW. The relation between pain-related fear and disability: a meta-analysis. J Pain. 2013;14(10):1019-1030. https://doi.org/10.1016/j.jpain.2013.05.005
  36. Hursey KG, Jacks SD. Fear of pain in recurrent headache sufferers. Headache. 1992;32(6):283-286.  https://doi.org/10.1111/j.1526-4610.1992.hed3206283.x
  37. Black AK, Fulwiler JC, Smitherman TA. The role of fear of pain in headache. Headache. 2015;55(5):669-679.  https://doi.org/10.1111/head.12561
  38. Karimi L, Wijeratne T, Crewther SG, et al. The Migraine-Anxiety Comorbidity Among Migraineurs: A Systematic Review. Front Neurol. 2021;11:613372. https://doi.org/10.3389/fneur.2020.613372
  39. Broen MP, Narayen NE, Kuijf ML, et al. Prevalence of anxiety in Parkinson’s disease: A systematic review and meta-analysis. Mov Disord. 2016;31(8):1125-1133. https://doi.org/10.1002/mds.26643
  40. Marrie RA, Reingold S, Cohen J, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler. 2015;21(3):305-317.  https://doi.org/10.1177/1352458514564487
  41. Peres DS, Rodrigues P, Viero FT, et al. Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: A systematic review and meta-analysis. Brain Behav Immun Health. 2022;24:100484. https://doi.org/10.1016/j.bbih.2022.100484
  42. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology. 2002;59(5):674-678.  https://doi.org/10.1212/wnl.59.5.674
  43. Calma AD, Heffernan J, Farrell N, et al. The Impact of Depression, Anxiety and Personality Disorders on the Outcome of Patients with Functional Limb Weakness — Individual Patient Data Meta-Analysis. J Psychosom Res. 2023;175:111513. https://doi.org/10.1016/j.jpsychores.2023.111513
  44. van Dam MJ, van Meijel B, Postma A, Oudman E. Health problems and care needs in patients with Korsakoff’s syndrome: A systematic review. J Psychiatr Ment Health Nurs. 2020;27(4):460-481.  https://doi.org/10.1111/jpm.12587
  45. Vorobeychik G, Black D, Cooper P, Cox A. Multiple sclerosis and related challenges to young women’s health: Canadian expert review. Neurodegener Dis Manag. 2020;10(2s):1-13.  https://doi.org/10.2217/nmt-2020-0010
  46. Garrelfs SF, Donker-Cools BH, Wind H, et al. Return-to-work in patients with acquired brain injury and psychiatric disorders as a comorbidity: A systematic review. Brain Inj. 2015;29(5):550-557.  https://doi.org/10.3109/02699052.2014.995227
  47. Tauil CB, Grippe TC, Dias RM, et al. Suicidal ideation, anxiety, and depression in patients with multiple sclerosis. Arq Neuropsiquiatr. 2018;76(5):296-301.  https://doi.org/10.1590/0004-282X20180036
  48. Becker E, Orellana Rios CL, et al. Anxiety as a risk factor of Alzheimer’s disease and vascular dementia. Br J Psychiatry. 2018;213(5):654-660.  https://doi.org/10.1192/bjp.2018.173
  49. Stein C, O’Keeffe F, Strahan O, et al. Systematic review of cognitive reserve in multiple sclerosis: Accounting for physical disability, fatigue, depression, and anxiety. Mult Scler Relat Disord. 2023;79:105017. https://doi.org/10.1016/j.msard.2023.105017
  50. Alwhaibi M, Alhawassi TM. Humanistic and economic burden of depression and anxiety among adults with migraine: A systematic review. Depress Anxiety. 2020;37(11):1146-1159. https://doi.org/10.1002/da.23063
  51. Cox RC, Olatunji BO. A systematic review of sleep disturbance in anxiety and related disorders. J Anxiety Disord. 2016;37:104-29.  https://doi.org/10.1016/j.janxdis.2015.12.001
  52. Neznanov NG, Martynikhin IA, Mosolov SN. Diagnosis and therapy of anxiety disorders in the Russian Federation: results of a survey of psychiatrists. Sovremennaia Terapiia Psikhicheskikh Rasstroistv. 2017;2:2-13. (In Russ.). https://doi.org/10.21265/PSYPH.2017.41.6437
  53. Kujanpää TS, Jokelainen J, Auvinen JP, Timonen MJ. The association of generalized anxiety disorder and Somatic Symptoms with frequent attendance to health care services: A cross-sectional study from the Northern Finland Birth Cohort 1966. Int J Psychiatry Med. 2017;52(2):147-159.  https://doi.org/10.1177/0091217417720894
  54. Neverovskii DV, Sluchevskaia SF, Parfenov VA. Differential diagnosis of discirculatory encephalopathy in outpatient practice. Nevrologiya, Neiropsikhiatriya i Psikhosomatika. 2013;2:38-42. (In Russ.).
  55. Bhattacharya S, Goicoechea C, Heshmati S, et al. Efficacy of cognitive behavioral therapy for anxiety-related disorders: A meta-analysis of recent literature. Curr Psychiatry Rep. 2023;25(1):19-30.  https://doi.org/10.1007/s11920-022-01402-8
  56. Hendriks SM, Spijker J, Licht CM, et al. Long-term disability in anxiety disorders. BMC Psychiatry. 2016;16:248.  https://doi.org/10.1186/s12888-016-0946-y
  57. Norman I, Ryrie I, eds. The Art and Science of Mental Health Nursing: Principles and Practice. 4th ed. London: McGraw-Hill Education. 2018.
  58. Thompson E. Hamilton Rating Scale for Anxiety (HAM-A). Occup Med (Lond). 2015;65(7):601.  https://doi.org/10.1093/occmed/kqv054
  59. Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016;39:24-31.  https://doi.org/10.1016/j.genhosppsych.2015.11.005
  60. Brennan C, Worrall-Davies A, McMillan D, et al. The Hospital Anxiety and Depression Scale: a diagnostic meta-analysis of case-finding ability. J Psychosom Res. 2010;69(4):371-378.  https://doi.org/10.1016/j.jpsychores.2010.04.006
  61. World Health Organization. International statistical classification of diseases and related health problems, 10th revision, Fifth edition, 2016. World Health Organization. Available at: https://iris.who.int/handle/10665/246208
  62. Lado FA, Ahrens SM, Riker E, et al. National Association of Epilepsy Guidelines for Specialized Epilepsy Centers Panel. Guidelines for Specialized Epilepsy Centers: Executive Summary of the Report of the National Association of Epilepsy Centers Guideline Panel. Neurology. 2024;102(4):e208087. https://doi.org/10.1212/WNL.0000000000208087
  63. American Epilepsy Society. Anxiety Disorders in Children with Epilepsy: Features, Causes, Diagnosis, and Treatment Approach. AES Clinical Guidance, 2023. Available at: https://aesnet.org/docs/default-source/pdfs-clinical/43200075_anxiety-disorders_childrenwithepilepsy_final_8_9_23.pdf?sfvrsn=26974f67_1
  64. American Epilepsy Society. Anxiety Disorders in Adults with Epilepsy: Features, Causes, Diagnosis, and Treatment Approach. AES Clinical Guidance, 2023. Available at: https://aesnet.org/docs/default-source/pdfs-clinical/42981132_anxiety-disorders_adultswithepilepsy_final_8_9_23.pdf?sfvrsn=4f427c30_1
  65. Clinical guidelines of the Ministry of Health of the Russian Federation «Epilepsy and epileptic status in adults and children — 2021». (In Russ.). Accessed: 10.09.2024. URL: https://cr.minzdrav.gov.ru/recomend/741_1
  66. Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(2 Suppl 2):45-49. 
  67. National Institute for Health and Care Excellence (NICE). Headaches in over 12s: diagnosis and management [Internet]. London: NICE. 2012 [cited 2024 Sep 10]. Available from: https://www.nice.org.uk/guidance/cg150/resources/headaches-in-over-12s-diagnosis-and-management-pdf-35109624582853
  68. https://cr.minzdrav.gov.ru/schema/295_2  https://cr.minzdrav.gov.ru/schema/295_2
  69. American Society of Anesthesiologists. Practice Guidelines for Chronic Pain Management. Anesthesiology. 2022;136(3):521-540. 
  70. American Heart Association/American Stroke Association. Guidelines for the Early Management of Patients with Acute Ischemic Stroke. Stroke. 2019;45(8):50-e418. https://doi.org/10.1161/STR.0000000000000211
  71. American Heart Association/American Stroke Association. Guidelines for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack. Stroke. 2021;52(7):e483-e484. https://doi.org/10.1161/STR.0000000000000375
  72. https://cr.minzdrav.gov.ru/recomend/457_2  https://cr.minzdrav.gov.ru/recomend/457_2
  73. Clinical guidelines of the Ministry of Health of the Russian Federation «Anxiety-phobic disorders in adults» — 2021. (In Russ.). Accessed: 11.09.2024. URL: https://cr.minzdrav.gov.ru/recomend/455_2
  74. Clinical guidelines of the Ministry of Health of the Russian Federation «Post-traumatic stress disorder» — 2021. (In Russ.). Accessed: 11.09.2024. https://cr.minzdrav.gov.ru/recomend/753_1
  75. Clinical guidelines of the Ministry of Health of the Russian Federation «Ischemic stroke and transient ischemic attack» — 2021. (In Russ.). Accessed: 11.09.2024. https://cr.minzdrav.gov.ru/recomend/171_2
  76. Nguyen N, Fakra E, Pradel V, et al. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol. 2006;21(3):139-49.  https://doi.org/10.1002/hup.757
  77. Alexandrovsky YA, Krasnov VN, Neznanov NG, et al. Efficacy of etifoxine compared to phenazepam in the treatment of patients with adjustment disorders (open randomized controlled trial). Russian Psychiatric Journal. 2010;(1):80-84. (In Russ.).
  78. Vicente B, Saldivia S, Hormazabal N, et al. Etifoxine is non-inferior than clonazepam for reduction of anxiety symptoms in the treatment of anxiety disorders: a randomized, double blind, non-inferiority trial. Psychopharmacology (Berl). 2020;237(11):3357-3367. https://doi.org/10.1007/s00213-020-05617-6
  79. Choi YM, Kim KH. Etifoxine for pain patients with anxiety. Korean J Pain. 2015;28(1):4-10.  https://doi.org/10.3344/kjp.2015.28.1.4
  80. Rupprecht R, Pradhan AK, Kufner M, et al. Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options. Eur Arch Psychiatry Clin Neurosci. 2023;273(7):1477-1487. https://doi.org/10.1007/s00406-022-01532-3
  81. Wolf L, Bauer A, Melchner D, et al. Enhancing neurosteroid synthesis--relationship to the pharmacology of translocator protein (18 kDa) (TSPO) ligands and benzodiazepines. Pharmacopsychiatry. 2015;48(2):72-77.  https://doi.org/10.1055/s-0034-1398507
  82. Gromova OA, Torshin IYu. Systematic analysis of fundamental and clinical studies on etifoxine. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(5):48-56. (In Russ.). https://doi.org/10.17116/jnevro202312305148
  83. Kokova VY, Zagorchev PI, Apostolova EG, et al. Etifoxine does not impair muscle tone and motor function in rats as assessed by in vivo and in vitro methods. Gen Physiol Biophys. 2020;39(2):179-186.  https://doi.org/10.4149/gpb_2019053
  84. Deplanque D, Machuron F, Waucquier N, et al. Etifoxine impairs neither alertness nor cognitive functions of the elderly: A randomized, double-blind, placebo-controlled crossover study. Eur Neuropsychopharm. 2018;28(8):925-932.  https://doi.org/10.1016/j.euroneuro.2018.05.011
  85. Nuss P, Ferreri F, Bourin M. An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action. Neuropsych Dis Treat. 2019;15:1781-1795. https://doi.org/10.2147/NDT.S200568
  86. Stein DJ. Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: A randomized controlled trial. Adv Ther. 2015;32(1):57-68.  https://doi.org/10.1007/s12325-015-0176-6
  87. Инструкция по медицинскому применению лекарственного препарата Стрезам (этифоксин). Регистрационный номер ЛСР-005103/08. Доступно по ссылке:
  88. Andriushchenko AV, Beskova DA, Romanov DV. Psikhofarmakoterapiia generalizovannoi trevogi (opyt primeneniia Strezama i Ataraxa). Psikhicheskie Rasstroistva v Obshchei Meditsine. 2010;(1):33-36. (In Russ.).
  89. Servant D, Graziani PL, Moyse D, Parquet PJ. Traitement du trouble de l’adaptation avec anxiété: évaluation de l’efficacité et de la tolérance de l’étifoxine par un essai en double aveugle contre produit de reference. Encephale. 1998;24(6):569-574. 
  90. Zeitler A, Kamoun N, Goyon S, et al. Favouring inhibitory synaptic drive mediated by GABA(A) receptors in the basolateral nucleus of the amygdala efficiently reduces pain symptoms in neuropathic mice. Eur J Neurosci. 2016;43(8):1082-1088. https://doi.org/10.1111/ejn.13217
  91. Aouad M, Charlet A, Rodeau JL, Poisbeau P. Reduction and prevention of vincristine-induced neuropathic pain symptoms by the non-benzodiazepine anxiolytic etifoxine are mediated by 3alpha-reduced neurosteroids. Pain. 2009;147(1-3):54-59.  https://doi.org/10.1016/j.pain.2009.08.001
  92. Aouad M, Petit-Demoulière N, Goumon Y, Poisbeau P. Etifoxine stimulates allopregnanolone synthesis in the spinal cord to produce analgesia in experimental mononeuropathy. Eur J Pain. 2014;18(2):258-268.  https://doi.org/10.1002/j.1532-2149.2013.00367.x
  93. Aouad M, Zell V, Juif PE, et al. Etifoxine analgesia in experimental monoarthritis: a combined action that protects spinal inhibition and limits central inflammatory processes. Pain. 2014;155(2):403-412.  https://doi.org/10.1016/j.pain.2013.11.003
  94. Girard C, Liu S, Cadepond F, et al. Etifoxine improves peripheral nerve regeneration and functional recovery. Proc Nat Acad Sci. 2008;105(51):20505-20510. https://doi.org/10.1073/pnas.0811201106
  95. Li M, Ren H, Sheth KN, et al. A TSPO ligand attenuates brain injury after intracerebral hemorrhage. FASEB. 2017;31(8):3278-3287. https://doi.org/10.1096/fj.201601377RR
  96. Ravikumar B, Crawford D, Dellovade T, et al. Differential efficacy of the TSPO ligands etifoxine and XBD-173 in two rodent models of multiple sclerosis. Neuropharmacology. 2016;108:229-237.  https://doi.org/10.1016/j.neuropharm.2016.03.053
  97. Zhou X, He X, He B, et al. Etifoxine promotes glial-derived neurotrophic factor induced neurite outgrowth in PC12 cells. Mol Med Rep. 2013;8(1):75-80.  https://doi.org/10.3892/mmr.2013.1474
  98. Dai T, Zhou X, Li Y, et al. Etifoxine promotes glia-derived neurite outgrowth in vitro and in vivo. J Reconstr Microsurg. 2014;30(6):381-388.  https://doi.org/10.1055/s-0034-1381751
  99. Verleye M, Heulard I, Gillardin JM. Investigation of the anticonvulsive effect of acute immobilization stress in anxious Balb/cByJ mice using GABA A-related mechanistic probes. Psychopharmacol. 2008;197(4):523-534.  https://doi.org/10.1007/s00213-007-1066-7
  100. Kruse HJ, Kuch H. Etifoxine: evaluation of its anticonvulsant profile in mice in comparison with sodium valproate, phenytoin and clobazam. Arzneimittelforschung. 1985;35(1):133-135. 
  101. Verleye M, Heulard I, Gillardin JM. The anxiolytic etifoxine protects against convulsant and anxiogenic aspects of the alcohol withdrawal syndrome in mice. Alcohol. 2009;43(3):197-206.  https://doi.org/10.1016/j.alcohol.2009
  102. Verleye M, Pansart Y, Gillardin J. Implication of 3alpha-reduced neurosteroids and their interaction with the GABAA receptor in the mechanism of action of etifoxine in rats. Brain Res. 2004;1023(1):42-50.  https://doi.org/10.1016/j.brainres.2004.07.032

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.